This website has been produced and funded by Novo Nordisk and is
intended for adult patients in the United Kingdom who have been
prescribed Wegovy®▼ (semaglutide injection). Side effect
reporting information can befound in the footer of this page.
Support materials for Wegovy®▼(semaglutide injection)
Here, you can discover a range of practical resources that have been developed to help support you in your treatment journey with Wegovy®.
How-to-use Wegovy® video
Watch this practical video guidance* on how to use your once-weekly Wegovy® FlexTouch® pen for patients on doses up to 2.4 mg once weekly. For those on the 7.2 mg dose please refer to this Dosing guide.
*Before you begin using your once-weekly Wegovy® FlexTouch® pen, always read the instructions carefully, and talk to your doctor, nurse or pharmacist about how to inject Wegovy® correctly.
This is not a real patient and is for illustrative purposes only.
Downloadable resources
The resources that are most relevant for your journey will depend on the reason you have been prescribed Wegovy®. You can find out more about each resource and its purpose in the descriptions below.
Weight management brochure
This brochure is intended for UK adult patients prescribed Wegovy® for weight management.
Read this brochure for further guidance if you’ve been prescribed Wegovy® for weight management.
How-to-use Wegovy® poster
Whether you’re injecting for the first time or just need a refresher, this step-by-step illustrated guidance takes you through how to inject your Wegovy® treatment.
Wegovy® 7.2 mg dosing guide
This brochure is intended for UK adult patients who have been prescribed the once weekly 7.2 mg maintenance dose of Wegovy® for weight management.
The information on this website does not replace the Patient Information Leaflet (PIL), which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice. Please refer to the PIL found in the product carton for further information on Wegovy®, further information on how to use Wegovy® and a full list of side effects, warnings and precautions.
Reporting side effects
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information promptly. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.